

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 5405.280			Serial No. 10/761,530
LIST OF DOCUMENTS CITED BY APPLICANT  (Use several sheets if necessary)				Applicants: Dwight D. Koeberl			
A1 of A1				Filing Date: January 21, 2004			Group: 1652 FBN
U. S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CLP	1.	US-6,328,958		Amalfitano et al.			
CLP	2.	US-6,582,692		Podsakoff et al.			
CLP	3.	US-2003/0219414		Podsakoff et al.			
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes   No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
CLP	4.	BARASH et al.; "Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression," <i>Biochemical and Biophysical Research Communications</i> 294: 835-842 (2002).					
	5.	CHENG et al., "Gene therapy progress and prospects: gene therapy of lysosomal storage disorders," <i>Gene Therapy</i> 10: 1275-1281 (2003).					
	6.	FRAITES et al., "Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors," <i>Molecular Therapy</i> 5: 5 571-578 (May 2002).					
	7.	HIRSCHHORN et al., "Glycogen Storage disease type II: acid $\alpha$ -glucosidase (acid maltase) deficiency," Wonsiewicz M, Noujaim S, Boyle P, eds, <i>The Metabolic and Molecular Bases of Inherited Disease</i> , 8 <sup>th</sup> Edition. New York: McGraw Hill; 2001, 3389-3420.					
	8.	KOEBERL et al., "Development of a hybrid adenovirus/adeno-associated virus for gene therapy in glycogen storage disease type II." Abstract presented at the Annual Meeting of the Pediatric Academic Societies; Seattle, WA (May 3 - 6, 2003)					
	9.	LIN et al., "Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency," <i>Gene Therapy</i> 9: 554-563 (2002).					
	10.	MARTIN-TOUAUX et al., "Muscle as a putative producer of acid $\alpha$ glucosidase for glycogenosis type II gene therapy," <i>Human Molecular Genetics</i> 11:14 1637-1645 (2002).					
	11.	RABEN et al., "Enzyme replacement therapy in the mouse model of Pompe disease," <i>Molecular Genetics and Metabolism</i> 80: 159-169 (2003).					
	12.	SUN et al., "Correction of glycogen storage disease type II (GSD II) by intramuscular administration of an adeno-associated virus (AAV) vector pseudotyped as AAV6," Abstract presented at the 6 <sup>th</sup> Annual Meeting of the American Society for Gene Therapy; Washington, D.C. (June 4 - 8, 2003).					
	13.	SUN et al., "Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector," <i>Molecular Therapy</i> 7:2 193-201 (2003).					
	14.	SUN et al., "Packaging of an AAV vector encoding human acid $\alpha$ -glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector," <i>Molecular Therapy</i> 7: 4 467-477 (2003).					
CLP	15.	WISSELAAR et al., "Structural and functional changes of lysosomal acid $\alpha$ glucosidase during intracellular transport and maturation," <i>Journal of Biological Chemistry</i> 268:3 2223-2231 (1993).					

EXAMINER  
\*EXAMINER

/Charles L. Patterson/

DATE CONSIDERED 09/12/2006  
Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 5405.280		Serial No. 10/761,530	
<b>LIST OF DOCUMENTS CITED BY APPLICANT</b> 				Applicants: Dwight D. Koeberl			
B1 of B1 <small>(See several sheets if necessary)</small>				Filing Date: January 21, 2004		Group: 1652	
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Subclass	Translation Yes   No
CLP	16	International Search Report PCT/US2004/001453	8/04	PCT			
CLP	17	WO 02/098466 A	12/02	PCT			
CLP	18	WO 00/34451 A	6/00	PCT			
CLP	19	WO 98/11206 A	3/98	PCT			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							

EXAMINER /Charles L. Patterson/ DATE CONSIDERED 09/12/2006  
 \*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**Substitute form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

**(use as many sheets as necessary)**

Sheet C1 of C1

110

DEC 06 2005

**Complete if Known**

Application Number	10/761,530
Filing Date	January 21, 2004
First Named Inventor	Koeberl et al.
Group Art Unit	1652
Examiner Name	Rao, Marjanath N. Charles Patterson
Attorney Docket Number	5405-280

## **U.S. PATENTS AND PATENT PUBLICATIONS**

## FOREIGN PATENT DOCUMENTS

## OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
CLP	23	Haberman, et al., "Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion," <i>Nature Medicine</i> , 9, 1076-1080, (2003).	
CLP	5 24	Haberman, et al., "Regulated Suppression of Focal Seizure Sensitivity by Adeno-Associated Virus (AAV) Vector-Dependent Galanin Secretion," <i>Abstract, Program No. 619.10</i> , Washington, DC: Society for Neuroscience (2002).	

Examiner Signature	/Charles L. Patterson/	Date Considered	09/12/2006
--------------------	------------------------	-----------------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.